Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9<i>H</i>-pyrimido[4,5-<i>b</i>]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor
Yujun Zhao(Shanxi Agricultural University), Shaomeng Wang(University of Michigan)
Cited by 42
Related Papers
Characterization of a Novel, Water-Soluble Hydrogen Sulfide–Releasing Molecule (GYY4137)
|Circulation|2008|831
The Slow-Releasing Hydrogen Sulfide Donor, GYY4137, Exhibits Novel Anti-Cancer Effects In Vitro and In Vivo
|PLoS ONE|2011|379
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
|Cancer Research|2014|337
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
|Journal of Medicinal Chemistry|2018|261
A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation
|Nature Communications|2017|93